Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Renal Cell Carcinoma
Both
Renal Cell Carcinoma
Trial Information
Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy
Inclusion Criteria:
- Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy
- Start of first palliative therapy within 1 year before enrollment of patient to
registry; since enrollment of 1000 Patients: start of first palliative therapy within
4 weeks before enrollment
Exclusion Criteria:
-
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Documentation of therapies
Outcome Time Frame:
9 years, 3 years per patient
Safety Issue:
No
Authority:
Germany: Ethics Commission
Study ID:
IOM RCC
NCT ID:
NCT00610012
Start Date:
December 2007
Completion Date:
Related Keywords:
- Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- MRCC
- Therapy-reality
- Observation
- Registry
- RCC
- ARCC
- Germany
- Metastatic Renal Cell Carcinoma
- Renal Cell Carcinoma
- Renal Cell Cancer
- Sorafenib
- Sunitinib
- Interferon
- Interleukin
- Temsirolimus
- Pazopanib
- Cytokines
- VEGF
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
